Case Studies & Whitepapers2026-03-11
Optimization of Synthetic Process and Metal-Chelation Impurity Control Strategy for Complex Peptide-based RDCs Download
Radionuclide-Drug
Conjugates (RDCs) are core carriers for the integrated diagnosis and treatment
of tumors, enabling simultaneous precise diagnosis and tumor killing. Among
them, peptide-based RDCs have become an important direction for cancer
treatment due to their high matching degree between half-life and
radionuclides, excellent targeting, and good safety. To date, more than 400
RDC-related clinical trials have been registered worldwide. Despite their broad
application prospects, R&D and m
More
News
More
Case Studies & Whitepapers2026-10-23
FAQ: Hot-Melt Extrusion Technology Empowers Innovative Drug Development
Is ASD development necessary when the API is already amorphous?
Case Studies & Whitepapers2026-09-25
Dual-Payload Conjugates: Addressing the CMC Challenges of a New Therapeutic Approach
Dual-payload conjugates—two mechanistically distinct payloads carried on a single targeting vehicle—represent the next technological frontier beyond conventional ADCs.
